Focal therapy (FT) for prostate cancer, also referred to as partial gland ablation, aims to
reduce prostate cancer treatment morbidity while attaining sufficient oncological control …

Focal therapy for localised prostate cancer has gained attention over the last decade as
patients and clinicians attempt to find the" Holy Grail" of a cure for localised prostate cancer …

Purpose: Our aim was to assess oncologic, safety, and quality of life–related outcomes of
focal therapy with irreversible electroporation in men with localized prostate cancer …

Background: Current data on the use of irreversible electroporation (IRE) in the treatment of
prostate cancer (PCa) is limited. We aim to evaluate the safety, short-term functional and …

The extensive use of prostate-specific antigen (PSA) testing and improved imaging
technologies have resulted in an increased diagnosis of prostate cancer. Early diagnosis is …

Objectives To determine the safety, quality of life (QoL) and short‐term oncological
outcomes of primary focal irreversible electroporation (IRE) for the treatment of localized …

Purpose: Irreversible electroporation has attractive attributes for focal ablation, namely
nonthermal effect, precise demarcation of treatment and tissue selectivity. We report a …

Objectives To evaluate longer‐term oncological and functional outcomes of focal irreversible
electroporation (IRE) as primary treatment for localised clinically significant prostate cancer …

Background Focal irreversible electroporation (IRE) can be used to treat men with localised
prostate cancer (PCa) with reduced impact on quality of life (QoL). Objective To assess …

RESULTS: Fifteen consecutive men received focal IRE treatment (08/2011-09/2012) for low,
intermediate and highrisk disease (D'Amico classification) in 7%, 80% and 13 …